THERAPY DOSSIER · th-4cb60bc51eab

MAP4343 (3beta-methoxy-pregnenolone)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04157114 ↗PHASE2withdrawn

A Trial of MAP4343 Treatment, a Ligand of the Neurospecific Microtubule Associated Protein-2, for Alcohol Use Disorder

Alcohol Use Disorder

Enrolment: 0 · Results not recorded

NCT03870776 ↗PHASE2completed

Phase 2 Study of Daily Oral MAP4343 During 6 Weeks in Antidepressant Non-responders Experiencing a Major Depressive Episode

Depression

Enrolment: 126 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21704982 ↗2011Reported benefit

Treatment of experimental spinal cord injury with 3beta-methoxy-pregnenolone.

RatSpinal cord injuryContusionSprague-DawleyMaleSubcutaneousPost-traumatic; first injection up to 24 h after injury

Model: Thoracic spinal cord compression/contusion (three models)

Subcutaneous MAP4343 improved locomotor recovery and preserved motoneuron dendrites after spinal cord injury in three rat models.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…